Want to see IN:HALEOSLABS full AI Analyst Report?
HALEOSLABS Stock Chart & Stats
₹1105.00
₹4.55(0.36%)
At close: 4:00 PM EST
₹1105.00
₹4.55(0.36%)
Day’s Range― - ―
52-Week Range₹1,081.80 - ₹1,778.35
Previous CloseN/A
VolumeN/A
Average Volume (3M)48.00
Market Cap
₹4.61B
Enterprise Value₹4.25K
Total Cash (Recent Filing)₹15.71M
Total Debt (Recent Filing)₹697.87M
Price to Earnings (P/E)28.4
Beta0.97
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.1%
Share Statistics
EPS (TTM)48.10
Shares Outstanding3,023,287
10 Day Avg. Volume45
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio-1.50
Price to Book (P/B)1.69
Price to Sales (P/S)1.08
P/FCF Ratio-15.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
API Manufacturing PlatformThe company operates in an essential pharmaceutical-input segment, supplying APIs used in finished medicines. Domestic and export exposure provides a broad customer base and supports durable demand, although execution depends on quality, regulatory compliance, and customer retention.
FY2026 Revenue ReboundThe strong FY2026 revenue rebound indicates improving demand and renewed sales momentum across the business. Sustained growth would improve operating leverage and support capacity utilization, provided the company can convert higher sales into healthier margins and cash flow.
Manageable Leverage And Growing EquityModerate leverage and a growing equity base provide some financial resilience as the company funds operations and investment. This balance-sheet position offers more flexibility than a highly debt-dependent model, though rising debt could become a concern if profitability remains weak.
Bears Say
Sharp Gross-margin CompressionThe steep margin decline signals significant cost, pricing, product-mix, or utilization pressure. If persistent, it would limit earnings growth despite higher revenue and reduce the company’s ability to absorb input-cost inflation or competitive pricing in API markets.
Negative Free Cash FlowNegative free cash flow increases reliance on debt or equity funding to support investment and working capital. The pack also notes historical volatility and weak cash conversion, reducing confidence that reported earnings can consistently finance future growth internally.
Weak Earnings ConversionLower operating profitability and declining net income show that revenue growth is not translating efficiently into shareholder earnings. Positive but modest returns on equity, including roughly 8% in FY2026, point to limited profitability strength and execution risk.
SMS Lifesciences India Ltd. News
HALEOSLABS FAQ
What was SMS Lifesciences India Ltd.’s price range in the past 12 months?
SMS Lifesciences India Ltd. lowest stock price was ₹1081.80 and its highest was ₹1778.35 in the past 12 months.
What is SMS Lifesciences India Ltd.’s market cap?
SMS Lifesciences India Ltd.’s market cap is ₹4.61B.
When is SMS Lifesciences India Ltd.’s upcoming earnings report date?
SMS Lifesciences India Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 72 days.
How were SMS Lifesciences India Ltd.’s earnings last quarter?
SMS Lifesciences India Ltd. released its earnings results on Aug 05, 2026. The company reported ₹8.754 earnings per share for the quarter.
Is SMS Lifesciences India Ltd. overvalued?
According to Wall Street analysts SMS Lifesciences India Ltd.’s price is currently Overvalued.
Does SMS Lifesciences India Ltd. pay dividends?
SMS Lifesciences India Ltd. pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.1%. See more information on SMS Lifesciences India Ltd. dividends here
What is SMS Lifesciences India Ltd.’s EPS estimate?
SMS Lifesciences India Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Lifesciences India Ltd. have?
SMS Lifesciences India Ltd. has 3,023,287 shares outstanding.
What happened to SMS Lifesciences India Ltd.’s price movement after its last earnings report?
SMS Lifesciences India Ltd. reported an EPS of ₹8.754 in its last earnings report. Following the earnings report the stock price went down -10.178%.
Which hedge fund is a major shareholder of SMS Lifesciences India Ltd.?
Currently, no hedge funds are holding shares in IN:HALEOSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Lifesciences India Ltd.
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―